Lushang Freda Pharmaceutical (SH:600223) Shenwan Hongyuan Securities·2025-08-25 03:44Investment Rating - The investment rating for the company is "Outperform" (previously "Buy") [2][7] Core Insights - The company reported a decline in performance for the first half of 2025, with revenue of 1.79 billion yuan, down 7.1% year-on-year, and a net profit of 110 million yuan, down 15.2% year-on-year [7][10] - The cosmetics and pharmaceutical segments experienced a downturn, while the raw materials segment showed steady growth [7] - The company is focusing on brand marketing and leveraging AI in its sales strategy to enhance competitiveness in the cosmetics market [7] Financial Summary - Total revenue projections for 2025 have been adjusted to 3.987 billion yuan, with a slight year-on-year growth of 0.1% expected [6][7] - The forecast for net profit for 2025 is set at 262 million yuan, reflecting a 7.5% increase year-on-year [6][7] - The gross margin is expected to improve to 57.6% in 2025, up from 52.3% in the first half of 2025 [6][7]